All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub is pleased to present a visual abstract representing key data from a phase II trial (NCT03931291) evaluating eprenetapopt plus azacitidine as a post-allogeneic hematopoietic stem cell transplantation treatment for patients with TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
To download this visual abstract, click below.Download here
Efficacy and safety of eprenetapopt (APR-246) combined with azacitidine in patients with TP53-mutant MDS and oligoblastic AML
Around 20% of patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) and 30–40% of patients with...
Eprenetapopt with azacitidine for TP53-mutant MDS/AML: Results from two ongoing clinical trials
Patients with TP53-mutant myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience suboptimal responses to currently available...
Subscribe to get the best content related to AML delivered to your inbox